A股異動丨雙成藥業連續2日跌停 澄清重大資產重組存在不確定性
雙成藥業(002693.SZ)連續2日跌停,報16.33元刷新調整新低,自高點累計回撤近60%,總市值跌破70億元。消息上,公司1月2日晚間發佈股票交易異常波動及風險提示性公吿,公司正在籌劃重大資產重組事項。本次重組事項尚需履行必要的內部決策程序,並需經有權監管機構批准後方可正式實施,能否最終成功實施存在不確定性。值得注意的是,截至2024年前三季度,公司營業收入為1.27億元,淨利潤為負。根據相關規定,如果2024年度公司無法實現利潤總額、淨利潤或扣除非經常性損益後的淨利潤均為正,且營業收入低於3億元,將面臨退市風險警示。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.